Cardiovascular Disease Among Transgender Adults Receiving Hormone Therapy

  title={Cardiovascular Disease Among Transgender Adults Receiving Hormone Therapy},
  author={Carl G. Streed and Omar Harfouch and Francoise A. Marvel and Roger S. Blumenthal and Seth Shay Martin and Monica Mukherjee},
  journal={Annals of Internal Medicine},
Key Summary Points Cross-sex hormone therapy (CSHT) is associated with improved psychological functioning of transgender persons. CSHT, particularly with testosterone, is associated with worsening cardiovascular risk factors (such as increased blood pressure, insulin resistance, and lipid derangements) in transgender men but not with increases in cardiovascular morbidity or mortality. CSHT for transgender women has potential thromboembolic risk, and lower-dose transdermal and oral bioidentical… 

Gender-Affirming Hormone Therapy, Vascular Health and Cardiovascular Disease in Transgender Adults

This review explores the available evidence on the associations between gender-affirming hormones and cardiovascular events such as coronary artery disease, stroke, hypertension, thrombosis, lipid abnormalities, and diabetes mellitus.

An Observational Study of Hypertension and Thromboembolism Among Transgender Patients Using Gender-Affirming Hormone Therapy

The protective association between progestins and HTN among TW is reassuring, and more research is needed to examine the effect of recent progestin, specifically medroxyprogesterone acetate, on TE among transwomen.

Response to: Cardiovascular Risk Profile of Transgender Women with HIV.

A retrospective study of cardiovascular risk characteristics of transgender women with HIV compared to cisgender men with HIV concluded that transgender women had lower hemoglobin levels and higher rates of anemia with no significant difference in prevalence of traditional cardiovascular risk factors.

Transgender adults, gender-affirming hormone therapy and blood pressure: a systematic review

There is currently insufficient data to advise the impact of GHT on BP in transgender individuals and better quality research is essential to elucidate whether exogenous sex hormones modulateBP in transgender people and whether this putative alteration infers poorer cardiovascular outcomes.

Occurrence of Acute Cardiovascular Events in Transgender Individuals Receiving Hormone Therapy.

The incidences of acute/spontaneous strokes, myocardial infarctions, and venous thromboembolic events in transwomen and transmen receiving transgender hormone therapy (THT) are determined and compared with those reported in women and men from the general population.

Cross-Sex Hormones and Acute Cardiovascular Events in Transgender Persons

The authors' study quantitatively evaluated the potential effect of unmeasured confounders, including those mentioned by Ms. Goldstein and colleagues, and found that the results should not be interpreted as a reason for not prescribing hormone therapy.

Cardiac arrhythmias secondary to hormone therapy in trans women

It is proposed that hormone therapy in trans women may increase the risk of cardiac arrhythmias, and a larger database from which to collect information regarding the benefits and risks of treatment, including the potential side effect of arrh rhythmias is collected.

Prevalence and Predictors of Cardiovascular Disease and Risk Factors in Transgender Persons in the United States

In this contemporary cross-sectional nationally representative survey, CVD was prevalent in nearly 14% ofTGD persons, and TGD persons with CVD were older with lower annual income and had higher rates of smoking, lower rates of regular exercise, and higher ratesof smoking and chronic medical comorbidities.



Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex difference in cardiovascular disease pattern.

MtoF should not be treated with oral ethinyl estradiol, and transdermal estrogens are probably safer than oral estrogens, and pre-existing cardiovascular risks should be taken into consideration when prescribing and choosing the type of estrogens in cross-sex hormone administration (oral vs transDermal).

Long-term evaluation of cross-sex hormone treatment in transsexual persons.

Cross-sex hormone treatment appears to be safe in transsexual men, but a substantial number of transsexual women suffered from osteoporosis at the lumbar spine and distal arm, and more attention should be paid to decrease cardiovascular risk factors during hormone therapy management.

Mortality and morbidity in transsexual patients with cross-gender hormone treatment.

Established risk factors for coronary heart disease are unrelated to androgen-induced baldness in female-to-male transsexuals.

None of the CHD risk factors at follow-up, nor proportional changes, was associated with the degree MPB, except that there was an unexpected tendency of lower fasting glucose levels in balding subjects, and the findings do not support the idea that MPB serves as an indicator of increasedCHD risk through androgenic effects on classic CHDrisk factors.

Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study.

Morbidity rate during cross-sex hormone therapy was relatively low, especially in trans men, and a higher prevalence of venous thrombosis, myocardial infarction, CVD, and type 2 diabetes in trans women than in the control population.

Thrombotic issues in transgender medicine: A review

This review highlights the current interventions available in transgender medicine and related potential hematologic complications, and it suggests simple, evidence‐based management going forward.

Conjectures concerning cross-sex hormone treatment of aging transsexual persons.

Cross-sex hormones may be continued into old age but monitoring for cardiovascular disease and malignancies, both of the old and new sex, is recommended.

Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative.

Conjugated equine estrogens provided no overall protection against myocardial infarction or coronary death in generally healthy postmenopausal women during a 7-year period of use.

Breast cancer development in transsexual subjects receiving cross-sex hormone treatment.

Cross-sex hormone treatment of transsexual subjects does not seem to be associated with an increased risk of malignant breast development, in either MtF or FtM transsexual individuals.

Sexual orientation disparities in cardiovascular biomarkers among young adults.